ORGANOGENESIS HOLDINGS INC. Deferred Income Tax Expense (Benefit)
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Deferred Income Tax Expense (Benefit) of $29.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $45.33M.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$15.37M.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $15.63M.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$3.84M.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for fiscal 2025 was $9.50M.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for fiscal 2024 was -$10.72M, a 632.75% decline from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for fiscal 2023 was $2.01M, a 1.62% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. deferred income tax expense (benefit) for fiscal 2022 was $1.98M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $29.96M 10-Q · filed 2026-08-06 | $45.59M derived: sum of 3 quarters · filed 2026-08-06 | $41.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$15.37M 10-Q · filed 2026-05-07 | $258.00K derived: sum of 2 quarters · filed 2026-05-07 | -$3.58M derived: sum of 3 quarters · filed 2026-05-07 | -$4.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.79M derived: sum of 2 quarters · filed 2026-02-26 | $10.77M derived: sum of 3 quarters · filed 2026-08-06 | $9.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$3.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.86M derived: sum of 2 quarters · filed 2026-08-06 | -$6.13M 10-Q · filed 2025-11-06 | -$8.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.29M 10-Q · filed 2026-08-06 | -$5.12M derived: sum of 3 quarters · filed 2026-08-06 | -$7.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.27M 10-Q · filed 2026-05-07 | -$4.10M derived: sum of 2 quarters · filed 2026-05-07 | -$6.30M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.03M derived: sum of 2 quarters · filed 2026-02-26 | -$10.72M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$7.89M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$5.69M 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.01M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $1.98M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | -$31.98M 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $112.00K 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $111.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $186.00K 10-K · filed 2021-03-16 | |||
| 2017-12-31 | -$7.30M 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |